Ablynx, a biopharmaceutical company, headquartered in Ghent, Belgium, is engaged in the discovery and development of Nanobodies® to treat a range of serious human diseases. Nanobodies® are a novel class of antibody-derived theraputic proteins. Because of their small size, unique structure and extreme stability, Nanobodies® combine the advantages of conventional antibody theraputics with the key features of small-molecule drugs.

The power of Ablynx's discovery platform has resulted in a Nanobody® development candidate, ALX-0081, which became the first ever single domain antibody to enter clinical trials. Ablynx reported the final positive results from its Phase I study in December 2007.

Speaker Profile

Edwin Moses, CEO and Chairman of the Board

After completing his post-doctoral research in Germany, Edwin began a commercial career with successful periods spent at Amersham International, Enzymatix and Raggio-Italgene. From 1993-2001 as CEO and then Chairman he was responsible for the growth of Oxford Asymmetry (OAI) through a series of venture rounds cumulating in a floatation (LSE) in 1998 at a value of €175M followed by a sale of the company to Evotec Biosystems in 2000 for €460M. In March 2006, Edwin accepted the offer by Ablynx’s Board to extend his role as Chairman to include that of CEO. Edwin has been Chairman of Ablynx since 2004.